BioCanRx has established a Point-of-Care (POC) Cell Manufacturing Committee, made up of scientists, clinicians and guided by subject matter experts, to oversee the expansion and integration of our POC manufacturing sites into a functional network across Canada. The benefit of our POC network is to enable access to cutting-edge, cellular cancer immunotherapies to Canadians through clinical trials.
Members of the committee
 |
 |
 |
 |
| Dr. Harry Atkins Scientist, Cancer Therapeutics Program, Ottawa Hospital Research Institute Attending Physician, Blood and Marrow Transplant Program, The Ottawa Hospital Associate Professor, Clinical Hematology, University of Ottawa |
Dr. John Bell Scientific Director, BioCanRx Senior Scientist, The Ottawa Hospital Professor, uOttawa |
Dr. Kevin Hay Clinical Scientist and Hematologist, The Leukemia/Bone Marrow Transplant Program of BC, BC Cancer |
Dr. Michael Jamieson Advisor, Research and Innovation Partnerships, Queen’s University Partnerships and Innovation |
 |
 |
 |
 |
| Dr. Natasha Kekre Associate Scientist, Clinical Epidemiology Program, Ottawa Hospital Research Institute Hematologist, Blood and Marrow Transplant Program, The Ottawa Hospital Assistant Professor, University of Ottawa |
Dr. Brad Nelson Distinguished Scientist and Director, Deeley Research Centre Scientific Co-director, Immunotherapy Program, BC Cancer |
Dr. Christine Williams Deputy Director, Ontario Institute for Cancer Research (OICR) |
Dr. Armin Gerbitz Staff Physician, Hans Messner Allogeneic Transplantation Program; Professor of Medicine, University of Toronto |
BioCanRx Staff
 |
 |
 |
|
| Dr. Stéphanie Michaud, President and Chief Executive Officer | Dr. Jennifer Quizi, Director, Biotherapeutics Manufacturing Operations | Dr. Megan Mahoney, Director, Scientific Affairs and Training Programs |
